Pretreatment 18F‐FDG uptake heterogeneity may predict treatment outcome of combined Trastuzumab and Pertuzumab therapy in patients with metastatic HER2 positive breast cancer
Abstract Objective Intra-tumoral heterogeneity of 18F‐fluorodeoxyglucose (18F‐FDG) uptake has been proven to be a surrogate marker for predicting treatment outcome in various tumors. However, the value of intra-tumoral heterogeneity in metastatic Human epidermal growth factor receptor 2(HER2) positi...
Guardat en:
| Autors principals: | , , , , , , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
BMC
2023-09-01
|
| Col·lecció: | Cancer Imaging |
| Matèries: | |
| Accés en línia: | https://doi.org/10.1186/s40644-023-00608-0 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|